ArticleAdvances in therapy2026
Assessment of the Value of Nivolumab Plus Ipilimumab for Treating Microsatellite Instability-High/Mismatch Repair Deficiency Metastatic Colorectal Cancer: Indirect Treatment Comparison and Cost-Effectiveness Analysis.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04008030 (A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionColorectal cancer (CRC) is the third most common cancer and has the second highest global economic burden of all cancers. Among metastatic CRC (mCRC) cases, 4-5% are microsatellite instability-high/mismatch repair deficiency (MSI-H/dMMR) for which, up until recently, pembrolizumab was the recommended first-line treatment. This study has evaluated the cost-effectiveness of nivolumab plus ipilimumab versus pembrolizumab and chemotherapy in previously untreated, MSI-H/dMMR mCRC patients.
methodsA three-state semi-Markov model with a lifetime horizon was developed adopting a United States (US) healthcare payer perspective. Effectiveness data for nivolumab plus ipilimumab and chemotherapy were sourced from Checkmate-8HW (NCT04008030). Indirect treatment comparisons (ITCs) using Checkmate-8HW and KEYNOTE-177 informed comparisons with pembrolizumab. Methods included time-varying parametric analysis, fractional polynomials and matching adjusted indirect comparison. Utilities, resource use and costs were derived from trial data, US databases and literature.
resultsNivolumab plus ipilimumab dominated pembrolizumab in the base case analysis, as a first-line MSI-H/dMMR mCRC treatment yielding lower costs and greater quality-adjusted life years (QALYs) (Δ-US$58,819; Δ2.32). Compared with chemotherapy, costs and QALYs increased (Δ$58,783; Δ3.49) resulting in an incremental cost-effectiveness ratio (ICER) of $16,849. Across ITC methods, QALY gains versus pembrolizumab ranged from 1.65 to 2.35. Dominance over pembrolizumab was not maintained across all cost variations in scenario analyses, although resulting ICERs remained below commonly accepted US willingness-to-pay thresholds. The parameters most impactful of the ICER include the frequency of inpatient admissions with progressed disease and variations in drug dosing.
conclusionsThis is the first study demonstrating that first-line treatment with nivolumab plus ipilimumab may offer significant health economic benefits over pembrolizumab when used to treat first-line MSI-H/dMMR mCRC patients. With QALY gains ranging from 1.65 to 2.35 across various ITC methodologies, nivolumab plus ipilimumab seems a compelling treatment option for first-line MSI-H/dMMR mCRC.
Indexed as
Identifiers
42709325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.